We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court has affirmed Shire Pharmaceuticals’ patents for Vyvanse, blocking efforts by five drugmakers to market generic versions of the attention deficit hyperactivity disorder drug. Read More
The owner of Turing Pharmaceuticals says he will reverse course after raising a public outcry this week by upping the price by 5,000 percent. Read More
Amgen and Allergan claim their biosimilar candidate is clinically equivalent to Roche’s blockbuster Avastin in adult patients with advanced non-small cell lung cancer. Read More
Amgen is hoping a Delaware judge will be more agreeable than a California court as it sues Hospira to slow the biosimilar maker from marketing its challenger to Epogen. Read More
An interim report shows that the FDA has conducted nearly 90 meetings with more than 50 drug companies interested in producing biosimilar products since 2013 at a cost of $65.9 million. Read More